



BIOHEART

Media Contact: Bioheart, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 954.835.1500
bioheart@bioheartinc.com

For Immediate Release

Kristin Comella, US STEM CELL (Bioheart) CSO, Speaks at World Stem Cell and Regenerative Medicine Congress

Sunrise, FL – September 14, 2015 – US STEM CELL, Inc. (in transition from Bioheart, Inc. (BHRT.OB)) – As a recognized scientific leader and patient advocate, Kristin Comella, US STEM CELL’s Chief Scientific Officer, was a top speaker at this year’s annual World Stem Cell and Regenerative Medicine Congress, which was held in Washington, DC on September 2nd and 3rd. From the many presentations on technological advancements and clinical achievements in stem cell therapeutics and regenerative medicine, Ms. Comella’s presentation highlighted the immediate health benefits and practical business implications of her work in launching the US Stem Cell Clinic and US Stem Cell Training business.

“Each year, as we advance from congress to congress, the promise of stem cells and regenerative medicine is highlighted as becoming ever nearer to a market reality,” stated Kristin Comella, “but at the US Stem Cell Clinic, it is a reality today.” “Our physician based stem cell treatments are generating positive patient outcomes in an expanding list of unmet medical needs. Further, our physician training programs are globally extending the knowledge we have obtained making stem cell treatments available to many thousands of patients. Accordingly, our business is growing from the practical application of advance science and medicine.”

A recap of the 2015 Annual World Stem Cells and Regenerative Medicine Congress is provided through Biotech Weekly at: <https://biotechweekly.ongoodbits.com/2015/09/09/special-edition#public-issue-reader>.

About U.S. Stem Cell, Inc.

US Stemcell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society. Our business, which includes three operating divisions (**US Stem Cell Training, Vetbiologics and US Stem Cell Clinic**) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows

generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

About Clearit, LLC.

ClearIt, LLC, a Delaware limited liability company, is a development stage company advancing novel platform technology in the care and treatment of human skin. The Company's patent pending Eraser System will in a single treatment, when cleared by the U.S. FDA, completely, safely, and at an affordable cost remove tattoos from human skin. The Company anticipates launching the ERASER System in early 2017.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2014, and its Quarterly Reports on Form 10-Q.